INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

← catalyst calendar

NCT03037164

Sponsored by Cerus Corporation (industry) · CERS — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

692actual

Sites

Countries

Puerto Rico, Turkey (Türkiye), United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2017-05-11

actual

When the study began enrolling

Primary completion

2026-07-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-12-30

estimated

The whole study's end, after follow-up

First posted

2017-01-31

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Anemia

Interventions

Device: INTERCEPT Blood System for Red Blood Cells
Device: Conventional (Control)

Primary outcomes

what the primary-completion date above is the date OF

Adjusted hemoglobin increment

measured 15 minutes - 24 hours post transfusion

Adverse Events

measured 28 days

Treatment emergent antibodies

measured 75 days

Publications

PMID 42186075 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CERS's whole pipeline · Catalyst calendar · Every registered study · What changed